BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy
← catalyst calendarNCT07597993 · readout in 955 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
109estimated
Sites
9
Countries
Oman, Qatar, Saudi Arabia +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-12 | actual | When the study began enrolling |
| Primary completion | 2029-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Intervention
- Drug: TDxd
Primary outcome
what the primary-completion date above is the date OFreal-world progression-free survival
measured 18 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed